Booster doses of Janssen


The Vaccines and Related Biological Products Advisory Committee (VRBPAC) is due to meet on 14 and 15 October to discuss the use of booster doses of the Moderna and Janssen COVID-19 vaccines. Both vaccines are currently licensed in the U.S. for emergency use to prevent COVID-19 in people 18 years of age and older. The committee will also hear presentations and discuss the available data on the use of a booster consisting of a vaccine different from the one used for the primary authorized or approved COVID-19 vaccination series (heterologous or “mix and match” booster).  

The committee will discuss, on separate days, amendments to the emergency use authorization, to allow boosters of the Moderna and of the Janssen COVID-19 vaccines in individuals 18 years of age and older.

Additionally, the committee will hear a presentation from the National Institute of Health’s National Institute of Allergy and Infectious Diseases, on the heterologous use of booster doses following primary series of the three COVID-19 vaccines currently authorized for use in the United States.



  • Share: